Adrenomed – Safe treatment of acute circulatory failure
Adrenomed will provide the means to rescue vascular integrity in critically ill patients with limited treatment options
Adrenomed is a clinical-stage biopharma company focussing on the development of a first-in-class monoclonal antibody (Adrecizumab) against the vasoactive Adrenomedullin system, as a new strategy for causative and safe treatment of acute circulatory failure, e.g. septic shock.
Industry
Therapeutics
